ASMB - アセンブリ―・バイオサイエンシズ (Assembly Biosciences Inc.) アセンブリ―・バイオサイエンシズ

 ASMBのチャート


 ASMBの企業情報

symbol ASMB
会社名 Assembly Biosciences Inc (アセンブリ―・バイオサイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アセンブリ・バイオサイエンス(Assembly Biosciences Inc.)はバイオテクノロジー会社である。同社はB型肝炎ウイルス(HBV)感染症の治療向け口腔治療薬及びジビオティックな微生物に健康を回復するように設計された経口合成生治療薬という2つのプラットフォーム・プログラムの開発に従事する。同社はHBVコア(HBc)タンパク質を直接的に標的とし、アロステリックに調節する低分子であるコアタンパク質アロステリックモジュレーター(CpAM)を発見した。マイクロビオムプログラムは、菌株の同定と選択プロセスを含む統合的プラットフォームと菌株の分離と増殖のための方法、下部胃腸(GI)管にライブ生物学的と従来の療法の標的経口送達を可能にする送達システムGEMICELを含む。このプラットフォームの主要製品候補であるAB-M101はクロストリジウム・ディフィシル感染症の治療薬として開発中である。   アセンブリ―・バイオサイエンシズは米国のバイオ医薬品会社。主にB型肝炎ウィルス(HBV)やクロストリジウム・ディフィシル(CDAD)などの感染症疾患の新治療薬の開発・商品化に焦点を当てる。研究開発施設をサンフランシスコ及びニューヨークに置く。本社はニューヨーク。   Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
本社所在地 11711 North Meridian Street Suite 310 Carmel IN 46032 USA
代表者氏名 Derek A. Small デレク・A・スモール
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 212-554-4388
設立年月日 38626
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 79人
url www.assemblybio.com
nasdaq_url https://www.nasdaq.com/symbol/asmb
adr_tso
EBITDA EBITDA(百万ドル) -68.11952
終値(lastsale) 26.02
時価総額(marketcap) 662117383.58
時価総額 時価総額(百万ドル) 643.79590
売上高 売上高(百万ドル) 12.75800
企業価値(EV) 企業価値(EV)(百万ドル) 551.12366
当期純利益 当期純利益(百万ドル) -66.93408
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Assembly Biosciences Inc revenues increased from $3M to $6.8M. Net loss increased 56% to $43.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase from $10.9M to $26.2M (expense) Stock-based Compensation in SGA increase from $1.1M to $9.5M (expense).

 ASMBのテクニカル分析


 ASMBのニュース

   Assembly Biosciences (NASDAQ:ASMB) Research Coverage Started at Truist  2020/10/22 08:03:03 Transcript Daily
Truist initiated coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note published on Monday, The Fly reports. The brokerage issued a buy rating and a $55.00 target price on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on ASMB. ValuEngine lowered shares of Assembly Biosciences from a buy […]
   Analysts Set Expectations for Assembly Biosciences Inc’s FY2020 Earnings (NASDAQ:ASMB)  2020/10/21 16:09:20 Transcript Daily
Assembly Biosciences Inc (NASDAQ:ASMB) – Equities researchers at Truist Securiti issued their FY2020 earnings per share estimates for Assembly Biosciences in a note issued to investors on Monday, October 19th. Truist Securiti analyst N. Germino expects that the biopharmaceutical company will post earnings per share of ($1.96) for the year. Truist Securiti also issued estimates […]
   Truist Securiti Weighs in on Assembly Biosciences Inc’s FY2020 Earnings (NASDAQ:ASMB)  2020/10/21 15:34:52 Transcript Daily
Assembly Biosciences Inc (NASDAQ:ASMB) – Stock analysts at Truist Securiti issued their FY2020 earnings per share (EPS) estimates for shares of Assembly Biosciences in a report issued on Monday, October 19th. Truist Securiti analyst N. Germino forecasts that the biopharmaceutical company will post earnings per share of ($1.96) for the year. Truist Securiti also issued […]
   Assembly Biosciences (NASDAQ:ASMB) Now Covered by Truist  2020/10/21 07:28:43 Transcript Daily
Equities research analysts at Truist started coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report issued on Monday, The Fly reports. The firm set a “buy” rating and a $55.00 price target on the biopharmaceutical company’s stock. Truist’s price target indicates a potential upside of 258.31% from the stock’s previous close. Several other […]
   Assembly Biosciences Appoints Gina Consylman to Board of Directors  2020/10/20 12:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
   Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights  2020/08/05 20:05:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company…
   The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat  2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
   Assembly Biosciences : Signs Deal With BeiGene for Hep B Inhibitor | MarketScreener  2020/07/20 16:53:01 MarketScreener
By Chris Wack Assembly Biosciences Inc. shares were up 7% to $26.01 after it entered into a collaboration with BeiGene Ltd. in China for Assembly's portfolio of three clinical-stage core… | July 20, 2020
   BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge  2020/07/20 11:53:03 Smarter Analyst
BeiGene (BGNE) and Assembly Biosciences (ASMB) have announced a new collaboration in China for Assembly’s three clinical-stage core inhibitor candidates for the treatment of chronic … The post BeiGene, Assembly Bio Ink $540M China HBV Deal; Shares Surge appeared first on Smarter Analyst .
   Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection  2020/07/20 10:30:00 GlobeNewswire
-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million…
   Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020  2020/05/19 20:05:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that it will hold its 2020 Annual…
   Why Assembly Biosciences (ASMB) Stock Might be a Great Pick  2020/05/15 15:14:00 Zacks Investment Research
Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know  2020/02/20 17:31:52 Zacks Investment Research
Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Hedge Funds Are Selling Assembly Biosciences Inc (ASMB)  2019/11/06 21:40:22 Yahoo Finance
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen
   The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO  2019/10/10 11:31:01 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: …

 関連キーワード  (医薬品 米国株 アセンブリ―・バイオサイエンシズ ASMB Assembly Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)